

Rociletinib

Catalog No: tcsc1631



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g

Size: 10g



Specifications

CAS No:

1374640-70-6

Formula:

$C_{27}H_{28}F_3N_7O_3$

Pathway:

JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

Target:

EGFR;EGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 43 mg/mL (77.40 mM)

Alternative Names:

CO-1686;AVL-301;CNX-419

Observed Molecular Weight:

555.55


Product Description

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFR L858R/T790M and EGFR WT are 21.5 nM and 303.3 nM, respectively.

IC50 & Target: K_i : 21.5 nM (EGFR L858R/T790M), 303.3 nM (EGFR)

In Vitro: Rociletinib (CO-1686) (0.1 μ M) inhibits EGFR potently and irreversibly, and inhibits more than 50% of 23 targets. Rociletinib potently and selectively inhibits growth of NSCLC cells expressing mutant EGFR and induces apoptosis. Rociletinib resistant NSCLC cell lines are sensitive to AKT inhibition^[1].

In Vivo: Rociletinib (CO-1686) (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. Rociletinib (CO-1686) (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!